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study showed ﬁndings consistent with endometrial stromal tumor:
positive for vimentin, CD 10, smooth-muscle actin, and estrogen
and progesterone receptors. The cell proliferation index (Ki-67)
was less than 10%.
In view of the diagnosis, repeat laparotomy and total hysterectomy
or increased margins were suggested to the patient. However, the
patient declined any type of surgery before attempting pregnancy, as
she wished to have offspring and, therefore, underwent a completeIntroduction
Endometrial stromal tumors are extremely rare and account for
fewer than 0.2% of all malignant uterine tumors. Mitotic rates do
not separate endometrial stromal sarcoma (ESS) into low (≤10 high
power ﬁelds) and high (>10 high power ﬁelds) grade as in the
past. In fact, inﬁltrating tumors composed of cells resembling the
proliferative phase of the endometrium should be classiﬁed as ESS
regardless of the number of mitoses. Conversely, undifferentiated
ESS (UESS) is the former “high-grade sarcoma.”
The natural course of ESS is characterized by slow clinical progres-
sion, local recurrences (in the pelvis, ovaries, and intestinal wall) and
occasional metastases, whereas UESS is extremely aggressive and
survival is limited.Case description
The patient was a nulligravida 32-year-old woman. At age
28 years the patient was diagnosed with a small myoma of approxi-
mately 3 cm that had gradually grown to 80×61 mm with worsen-
ing of hypermenorrhea (Fig. 1). At age 32 years she underwent
laparotomy for myomectomy; the histologic diagnosis was ESS
with 8 mitoses per 10 highly magniﬁed ﬁelds and inﬁltrated radialics and Gynecology, Hospital




-ND license.study with tumor markers, repeat endometrium biopsy, magnetic
resonance imaging, and positron-emission tomography-computed
tomography (PET-CT), all with negative results. Progestin treatment
with megestrol acetate 80 mg/d was initiated, and the dose was subse-
quently doubled 1 month after treatment was started.
Sixteen months after the surgery, the patient decided to consult a
fertility clinic to assess a possible pregnancy. The couple was immedi-
ately included in an in vitro fertilization program. The oocytes were
vitriﬁed so that the procedure could be carried out once the endome-
trium was physiologically prepared. Following a failed fresh embryo
transfer cycle, two cryopreserved embryos were transferred and a
twin dichorionic-diamniotic pregnancy resulted. The course was nor-
mal except for threat of preterm delivery. Spontaneous membrane
rupture occurred prematurely at 32 weeks. The patient was informed
of the option to undergo c-section and hysterectomy during the same
surgery, but declined because the twins were premature (32 weeks)
and their course was unknown (weight 1700 g and 1710 g; Apgar
scores of 9/10 for both). The uterine cavity was found to be normal
during the laparotomy; however, a 3-cm myometrium-dependent
formation of hard consistency was observed in the left horn and on
top of the previous scarwas observed. The placenta was sent for further
study to the anatomic pathology department, with no unusual charac-
teristics. The patient was informed of the surgical ﬁndings during
the c-section, but preferred to postpone the hysterectomy until the in-
fants had progressed adequately. Breast-feeding was initiated, but the
patient had spontaneous menstruation from the second month despite
lactation. Based on the 2-month postpartum follow-up consisting of
cytology, ultrasound, laboratory workup, and hysteroscopy plus repeat
endometrial biopsy, the patient was diagnosed with proliferative
endometrium. Sixmonthspostpartum, the ultrasound revealed a uterus
of 7.8×6.4 cm with a cavity distorted by a hypodense nodule originat-
ing from the myometrium of 34×26 mm. Another nodule of 31×26
mmwas observed next to the ﬁrst, on the posterior aspect of the uterus.
Because recurrent or persistent disease was suspected and the infants
had progressed adequately, the patient underwent hysterectomy
Fig. 1. Transvaginal ultrasound. Note the uterus with presumed leiomyoma. Also note
the myoma vascularization on Doppler.
Fig. 3. Detailed view of tumor cells composed of a uniform proliferation of oval or
spindle-shaped cells, oval nuclei and scant cytoplasms, that swirl around small vessels.
No atypias or increase in mitotic rates are observed (original magniﬁcation×20).
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well as from a small adhesion in the fundus of the uterus and intraoper-
atively found to be benign on histology. The deﬁnitive anatomical
pathology diagnosis was ESS, International Federation of Gynecology
and Obstetrics (FIGO) stage IB (IC in the FIGO 1988 classiﬁcation),
with immunohistochemistry positive for CD 10 and for estrogen and
progesterone receptors. The cell proliferation index was very low
(Ki 67b1%). The biopsy referred to as adhesion to serosal layer of the
uterus was diagnosed as two neoplastic islets with a diameter of 0.10Fig. 2. (composition). A, irregular nests and tumor irregularities that permeate the
myometrium (original magniﬁcation×4). B, strong staining in tumor cells with CD-10
immunohistochemical staining.and 0.25 mm. Therefore, the conﬁrmation of recurrent or persistent
disease was found after hysterectomy.
At the postoperative follow-up visit, the patient was asymptomatic
and the pelvic ultrasound and PET-CT scans were negative. Three cycles
of GnRh analogs were prescribed, followed by megestrol acetate
160 mg/d. The laboratoryworkup showed follicle-stimulating hormone
5 IU/L, luteinizing hormone 13 IU/L, and estradiol 38 pg/mL. Tumor
markers were negative. Five years after the diagnosis, the patient
remained asymptomatic and all follow-up was normal, except for a
slight elevation in CA-125 to 64 IU/mLwhich has persisted at the levels
of previous follow-up tests. All imaging tests (ultrasound, CT, PET-CT
scans) have remained negative.
Discussion
The immunohistochemical phenotype of ESS includes typical posi-
tive reactions for vimentin and CD10, and other markers (keratins,
smooth-muscle and muscle-speciﬁc actin, estrogen and progesterone
receptors) are often expressed. Of these, CD10 and smooth-muscle
actin are the most useful for diagnosis of ESS.
It is important to complete conservative surgery in young patients
once fertility is achieved, even if recurrent or persistent disease is not
suspected, as the risk of recurrence is high. In ESS,most authors propose
hysterectomy with double adnexectomy (Bohr and Thomsen, 1991)
followed by medroxyprogesterone acetate (71% estrogen- and 95%
progesterone-receptor expression) with a response rate of 46% and
disease stabilization of 46%.
Some authors (Shah et al., 2008) report that bilateral salpingo-
oophorectomy does not affect survival or recurrence time in cases of
stage I ESS (evidence level II-2) and, therefore, propose ovary-sparing
treatment in premenopausal women even though the tumor is
hormone-sensitive. Another paper (Stadsvold et al., 2005) reports a
case of ESS in a 16-year-old woman who underwent uterus- and
ovary-sparing treatment. However, the role of adnexectomy is contro-
versial. Other authors (Berchuck et al., 1990; Park et al., 2008) reported
that the highest recurrence rate in stage I was observed in patients with
ovaries and, therefore, most authors perform salpingo-oophorectomy
in these patients.
There are no clinical guidelines for young patients who desire to
preserve fertility, and we found only two cases of gestation after
UESS (Yan et al., 2010) or ESS (Delaney et al., 2012 Aug). In these
cases, conservative surgery is possible. This surgery is later completed
with another operation to increase the margins (Yan et al., 2010) and
wait for spontaneous pregnancy (Yan et al., 2010; Delaney et al., 2012
Aug) or proceed with in vitro fertilization as in our patient (this was
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to complete the surgery afterwards).
The usefulness of lymphadenectomy is still unknown, although
some authors report a higher incidence of lymph node involvement
(10%) than previously expected, which suggests that lymphadenecto-
my may play a role. This has not been conﬁrmed by other authors
(Shah et al., 2008).
Progesterone is used because it counteracts the proliferative effect
induced by estrogens. It has been reported that the lack of intratumoral
estrogen-sulfotransferase enzyme could allow estrogen levels to
encourage tumor growth and favor its progression. This is also the
case of aromatase inhibitors (letrozole) (Reich and Regauer, 2007)
because intratumoral aromatase expression has been observed in 80%
of these tumors andGnRH analogs are also used. The impact of hormonal
therapy is not well deﬁned in the early stages of the disease (Reich and
Regauer, 2007) and there is also no evidence for treatment duration.
It has been suggested that the treatment should last 5 years (and be
life-long for others) because the recurrence rate is 50% at 36 to
68 months or even years later and is not affected by adjuvant chemo-
therapy or radiation therapy. We treated our patient with megestrol
acetate 160 mg/d and without chemotherapy, whereas the authors of
(Yan et al., 2010) use 20 mg/d and adjunctive chemotherapy (etoposide
and cisplatin). Because the tumor is hormone-dependent, hormone re-
placement therapy and tamoxifen are contraindicated in premenopausal
patients.
Radiation therapy does not improve stage I prognosis and, therefore,
would only be necessary in UESS or when deep myometrial invasion is
present (Weitmann et al., 2002).
The prognosis of ESS conﬁned to the uterus (stage I) is relatively good,
and 5-year survival is 80% to 100%. The prognosis is less favorable in
women with advanced stages, who have a 5-year survival rate of 40% to
50%. The most important prognostic factors are staging, and for some au-
thors, extrauterine growth ismore closely related to recurrence andprog-
nosis than mitotic activity or DNA content. Even in stage I, the rate ofpelvic recurrence is 25% to 50%. Lastly, for (Stadsvold et al., 2005)
salpingo-oophorectomy, adjuvant radiation therapy, lymphadenectomy,
and the presence of affected lymphnodeswerenot signiﬁcant risk factors.
In conclusion, we found few literature cases (13) of pregnancy
after leiomyosarcoma diagnosis (Salman et al., 2007), and only one
case of pregnancy after UESS (Yan et al., 2010). Our case is the second
to be described in cases of ESS after the case reported in (Delaney
et al., 2012 Aug).
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